REHOVOT, Israel, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein
therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the Cantor
Fitzgerald Global Healthcare Conference, being held October 1-3 at the InterContinental New York Barclay Hotel in New York City.
The presentation will take place on Wednesday October 3rd, 4:35pm EST. Webcast of Mr. London’s presentation will
be available at http://wsw.com/webcast/cantor7/kmda/.
About Kamada
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a
late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification
of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other
plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles
given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s flagship product is
GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration.
Kamada markets GLASSIA® in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties
through local distributors. In addition to GLASSIA®, Kamada has a product line of six other plasma-derived pharmaceutical
products administered by injection or infusion that are marketed through distributors in more than 15 countries, including Israel,
Russia, Brazil, India and other countries in Latin America and Asia. Kamada has late-stage products in development, including an
inhaled formulation of AAT for the treatment of AAT deficiency, and in addition, it's intravenous AAT is in development for other
indications, such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada's rabies immune globulin (Human)
product received FDA approval for Post-Exposure Prophylaxis against rabies infection in August 2017 and was launched in the US
during Q1-2018. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing
more than 10 complementary products in Israel that are manufactured by third parties.
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
Bob@LifeSciAdvisors.com
